Cargando…

Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review

Cystinosis is a rare, autosomal recessive disorder leading to defective transport of cystine out of lysosomes. Subsequent cystine crystal accumulation can occur in various tissues, including the ocular surface. This review explores the efficacy of cysteamine hydrochloride eye drops in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makuloluwa, Achini K, Shams, Fatemeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789046/ https://www.ncbi.nlm.nih.gov/pubmed/29416314 http://dx.doi.org/10.2147/OPTH.S133516

Ejemplares similares

Treatment of corneal cystine crystal accumulation in patients with cystinosis
por: Shams, Fatemeh, et al.
Publicado: (2014)

Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride
por: Liang, Hong, et al.
Publicado: (2021)

Analysis of tear film in cystinosis patients treated with topical viscous cysteamine hydrochloride (Cystadrops(®))
por: Sergio, Petroni, et al.
Publicado: (2022)

Non-invasive intradermal imaging of cystine crystals in cystinosis
por: Bengali, Marya, et al.
Publicado: (2021)

Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023)

The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series
por: Biswas, Susmito, et al.
Publicado: (2018)

Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis
por: Peeters, Freya, et al.
Publicado: (2019)

Pancytopenia in a patient with cystinosis secondary to myelosuppression from cystine crystal deposition: a case report
por: Lyou, Yung, et al.
Publicado: (2015)

Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011)

Effects of long-term cysteamine treatment in patients with cystinosis
por: Ariceta, Gema, et al.
Publicado: (2017)

In vivo confocal microscopy and anterior segment optical coherence tomography follow-up of cysteamine treatment in corneal cystinosis
por: Ozdemir, Huseyin Baran, et al.
Publicado: (2019)

Cysteamine–bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
por: Jamalpoor, Amer, et al.
Publicado: (2021)

Importance of adherence to topical cysteamine in infantile ocular cystinosis: An illustrative case
por: Bayram-Suverza, Mauricio, et al.
Publicado: (2022)

Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations
por: Martín-Sabroso, Cristina, et al.
Publicado: (2021)

A new proof of evidence of cysteamine quantification for therapeutic drug monitoring in patients with cystinosis
por: Franzin, Martina, et al.
Publicado: (2022)

Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine
por: Linden, Simone, et al.
Publicado: (2020)

Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023)

The Pitfall of White Blood Cell Cystine Measurement to Diagnose Juvenile Cystinosis
por: Bondue, Tjessa, et al.
Publicado: (2023)

A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
por: van Stein, Christina, et al.
Publicado: (2021)

A monoclinic polymorph of cysteamine hydrochloride
por: Ahmad, Saeed, et al.
Publicado: (2009)

The sparkle in her eye: Crystal deposits in cornea, conjunctiva, meibombian glands, and iris in uncontrolled cystinosis
por: Baker, Dara R., et al.
Publicado: (2021)

Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults
por: Ariceta, Gema, et al.
Publicado: (2015)

Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives
por: Castro-Balado, Ana, et al.
Publicado: (2020)

Response to Cysteamine in Osteoclasts Obtained from Patients with Nephropathic Cystinosis: A Genotype/Phenotype Correlation
por: Quinaux, Thomas, et al.
Publicado: (2021)

Spectral domain optical coherence tomography-based retinochoroidal cystine crystal score: a window into infantile nephropathic cystinosis
por: Keidel, Leonie, et al.
Publicado: (2023)

Cysteamine bitartrate delayed‐release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open‐label study of treatment‐naïve patients <6 years of age with nephropathic cystinosis
por: Vaisbich, Maria Helena, et al.
Publicado: (2021)

Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine
por: De Leo, Ester, et al.
Publicado: (2022)

Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom
por: Lashilola, Seun, et al.
Publicado: (2023)

The TGM2 inhibitor cysteamine hydrochloride does not impact corneal epithelial and stromal wound healing in vitro and in vivo
por: Minella, A.L., et al.
Publicado: (2023)

A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
por: Berends, Cécile L., et al.
Publicado: (2021)

Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis
por: Xu, Xuegu, et al.
Publicado: (2019)

Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence
por: Castro-Balado, Ana, et al.
Publicado: (2022)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Safety evaluation and pharmacodynamics of minocycline hydrochloride eye drops
por: Li, Xiaoli, et al.
Publicado: (2022)

Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
por: Langman, Craig B., et al.
Publicado: (2014)

The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study
por: Bjerre, Anna, et al.
Publicado: (2023)

Infliximab eye drops treatment in corneal neovascularization
por: Voiculescu, OB, et al.
Publicado: (2015)

Propranolol eye drops in patients with corneal neovascularization
por: Filippi, Luca, et al.
Publicado: (2018)

A Single Drop of 0.5% Proparacaine Hydrochloride for Uncomplicated Clear Corneal Phacoemulsification
por: Joshi, Rajesh Subhash
Publicado: (2013)

A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis
por: Armas, Danielle, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ko55ej9t5sr3r5f6oh21h854sn